ロード中...
Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses
AIMS: Chlorzoxazone is the paradigm marker substrate for CYP2E1 phenotyping in vivo. Because at the commonly used milligram doses (250–750 mg) chlorzoxazone acts as an inhibitor of the CYP3A4/5 marker substrate midazolam, previous attempts failed to combine both drugs in a common phenotyping cocktai...
保存先:
| 出版年: | Br J Clin Pharmacol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6783597/ https://ncbi.nlm.nih.gov/pubmed/31222796 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.14040 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|